This CME-certified Webcast contains video and downloadable slides from 8th Annual W. Montague Cobb/NMA Scientific Symposium and Lectureship - Navigating the Complex World of Cancer Diagnosis and Care: How Can We Minimize Disparities?, a prIME Oncology educational activity that was held on July 28, 2013 during the NMA Annual Convention and Scientific Assembly in Toronto, Ontario, Canada.
Edith Mitchell, MD, FACP
Patient navigation programs: Tools for reducing disparities in access to diagnosis and treatment of cancer
Harold P. Freeman, MD
Case #1: Metastatic non-small cell lung cancer
Nasser Hanna, MD
Case #2: Gastric malignancy
David Ilson, MD, PhD
Case #3: Prostate cancer
Michael Carducci, MD
- Edith P. Mitchell, MD, FACP
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
- Michael A. Carducci, MD, FACP
Johns Hopkins University
Baltimore, Maryland, United States
- Harold P. Freeman, MD
Harold P. Freeman Patient Navigation Institute
New York, New York, United States
- Nasser Hanna, MD
Indiana University Cancer Center
Indianapolis, Indiana, United States
- David Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
This activity is intended for physicians and other healthcare professionals involved and/or interested in racial disparities in cancer incidence and outcomes.
After successful completion of this educational activity, participants should be able to better:
- Identify the implications of disparities on the diagnosis and treatment of patients with cancer and employ available resources that can overcome these disparities when appropriate
- Employ current evidence-based best practices when treating patients with non-small cell lung cancer and integrate recent data regarding the potential influence of disparities on clinical outcomes
- Integrate recent data from trials investigating novel therapeutic approaches for gastric cancer and use effective patient navigation practices to enhance patient outcomes
- Incorporate novel therapies and approaches to castration-resistant prostate cancer and consider the potential impact of disparities on patient management and outcomes
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.